StockLearn from Clustermicro · Stock Breakout ScannerStockLearn

Ajanta Pharma (AJANTPHARM)

Pharma · NSE · end-of-day 2026-10-19

₹3,298.90

Day change

-0.90%

1-year

+36.3%

From 52-week high

-11.3%

Weinstein stage

Stage 2

Minervini template

7/8

Ajanta Pharma closed at ₹3,298.90 on 2026-10-19, up 36% over the past year, 11% below its 52-week high. It meets 7 of 8 conditions of Minervini's trend template; Weinstein's stage analysis reads stage 2 - advancing; on earnings, it passes 4 of 5 SEPA checks. Over the year its annualised volatility was about 26%, with a largest fall of 13% from a peak.

About Ajanta Pharma

Ajanta Pharma Limited develops branded generics and specialty pharmaceuticals across ophthalmology, dermatology, cardiology, pain management, and anti-infective therapies. The company has established strong brands in domestic and international emerging markets. Research-driven product development supports sustainable expansion. Operational excellence and quality manufacturing strengthen competitiveness. Growth in specialty healthcare continues to create long-term opportunities.

Price, RSI and MACD

6M1Y2Y3Y

Price · +18.6% over the period

RSI (14) · 35.6

MACD (12, 26, 9) · histogram -23.70

Price · +35.5% over the period

RSI (14) · 35.6

MACD (12, 26, 9) · histogram -23.70

Price · -0.8% over the period

RSI (14) · 35.6

MACD (12, 26, 9) · histogram -23.70

Price · +96.3% over the period

RSI (14) · 35.6

MACD (12, 26, 9) · histogram -23.70

Price: daily close adjusted for splits and bonuses, dashed line the 150-day moving average. MACD: green line, orange dashed signal, bars the histogram. Longer periods are drawn from every second or third session.

Fundamentals

Market cap	Sales (TTM)	Net profit (TTM)	P/E	EPS (TTM)	P/B	ROE	ROE previous year	ROCE	Debt / equity	Free cash flow	EV / EBITDA	Beta
₹41,352 cr	₹5,776 cr	₹1,135 cr	36.3	90.84	9.13	25.4%	25.0%	32.7%	0.05	₹169 cr	26.7	0.53

Quarterly results

Quarter	Sales ₹ cr	Net profit ₹ cr	EPS	EPS YoY	Sales YoY	Net margin
Jun 2026	1,626	334	26.75	+30.9%	+24.8%	20.6%
Mar 2026	1,422	267	21.35	+18.6%	+21.5%	18.8%
Dec 2025	1,375	274	21.91	+17.8%	+20.0%	19.9%
Sep 2025	1,354	260	20.83	+20.6%	+14.1%	19.2%
Jun 2025	1,303	255	20.44	+4.6%	+13.8%	19.6%
Mar 2025	1,170	225	18.00	+11.8%	+11.0%	19.2%
Dec 2024	1,146	233	18.60	+11.5%	+3.7%	20.3%
Sep 2024	1,187	216	17.27	+11.3%	+15.4%	18.2%

Consolidated · EPS restated onto today's share count after splits and bonuses · net profit as filed.

Minervini SEPA — earnings checks 4 of 5 pass

Check	Result
Latest quarter EPS up 25%+ on a year ago	✓ Pass
EPS growth accelerating over 3 quarters	✓ Pass
Sales up 25%+, or sales growth accelerating	✓ Pass
Annual EPS up 25%+ in each of the last 2 years	✗ Fail
Net margin above the same quarter last year	✓ Pass

Investor methods

Method	Checks	Score	Verdict
Minervini	✓ Close above the 150- and 200-day averages ✓ 150-day above 200-day ✓ 200-day rising for a month ✓ 50-day above the 150- and 200-day ✗ Close above the 50-day ✓ At least 25% above the 52-week low · low 2,388.40 ✓ Within 25% of the 52-week high · high 3,718.20 ✓ RS percentile 70 or more · RS 77 Trend template - the gate, measured: a modest 21-day edge.	7/8	7 of 8
Weinstein	Stan Weinstein's stage analysis on the 30-week moving average.		Stage 2 - advancing
CAN SLIM	✓ C latest quarter EPS up 25%+ ✗ A annual EPS up 25%+ in each of the last 2 years · O'Neil asks 3; ~2 held ✓ N within 15% of the 52-week high · high 3,718.20 ✗ S more volume on up days than down days (50 sessions) · 0.79x ✗ L RS percentile 80 or more · RS 77 — I institutional sponsorship rising · shareholding not collected yet ✓ M market in an uptrend (40%+ of stocks above their 200-day) · breadth 45% William O'Neil's growth-leader checklist.	3/6	Average
Darvas	✓ Box top confirmed (3 sessions below the new high) · top 3,796.00 ✗ Box bottom confirmed (3 sessions holding) · bottom 3,269.90 ✗ Close above the box top · close 3,298.90 ✗ Volume at least 1.5x its 50-day average · 0.4x Nicolas Darvas's box: buy the breakout above a confirmed box after a new high.	49/100	In box
Turtle	✗ Close above the prior 55-session high · 3,796.00 ✗ Close above the prior 20-session high · 3,758.90 ✗ Close below the prior 20-session low · 3,269.90 Donchian channel breakout - the Turtle traders' entry.		No signal
Greenblatt	— Earnings yield (EBITDA / EV) · 3.7% — Return on capital (ROCE) · 32.7% Joel Greenblatt's Magic Formula: good businesses at good prices, ranked across all companies. Earnings yield uses EBITDA, as EBIT is not held separately.	63/100	Average
Graham	✗ Price at or below the Graham number · Graham number 859.37 ✗ P/E 15 or less · P/E 36.3 ✗ P/B 1.5 or less (or P/E x P/B 22.5 or less) · P/B 9.13 ✓ Current ratio 2 or more · 2.64 — 10 years of positive earnings, 20 of dividends · history not held Benjamin Graham's defensive-investor tests.	26/100	Expensive
Piotroski	✓ Profitable (ROA > 0) ✓ Operating cash flow positive ✗ ROA rising ✗ Cash flow above net profit (earnings quality) ✓ Long-term debt / assets falling ✗ Current ratio rising · 2.64 ✓ No new shares issued ✗ Margin rising (net margin) ✗ Asset turnover rising Joseph Piotroski's F-score, FY 2025 -> 2026.	4/9	Weak

Each method's own rules applied to this stock - information, not a buy or sell signal. All were tested on 2024-26 data; only the Minervini trend template showed a consistent edge.

Pharma sector — top 10 by 1-year return

Stock	1M %	3M %	6M %	1Y %	3Y %	5Y %	P/E	P/B	ROE %	ROCE %	ROA %	D/E	EV/EBITDA	₹ Cr	Sales TTM ₹ Cr	Profit TTM ₹ Cr	EPS	Beta
AJANTPHARM this stock	-7.4	-4.9	+18.6	+35.3	+86.2	+128.9	36.3	9.13	25.4	32.7	—	0.05	26.7	41,352	5,776	1,135	90.8	0.53
BLISSGVS	-8.0	+29.9	+147.2	+312.3	+606.5	+476.9	48.7	5.57	11.5	16.8	—	0.00	29.3	6,650	1,005	142	12.9	1.10
VENUSREM	+0.7	-5.9	+55.8	+252.6	+518.8	+242.4	18.3	3.21	16.8	21.9	—	0.00	13.7	2,130	811	116	86.9	0.88
INDSWFTLAB	-5.7	+50.4	+153.3	+247.2	+287.1	+472.2	51.6	2.21	3.2	3.9	—	0.01	33.4	3,056	665	57	6.8	0.78
MOREPENLAB	+0.5	+108.6	+194.2	+152.6	+242.7	+132.7	47.5	5.34	7.9	10.1	—	0.16	40.2	6,657	1,951	140	2.6	1.46
SHILPAMED	-14.2	+40.1	+113.1	+146.1	+421.3	+189.7	57.3	6.61	9.8	11.4	—	0.25	—	17,130	1,682	297	15.3	0.87
RUBICON	-15.1	-1.7	+60.3	+140.3	—	—	83.8	19.08	22.4	—	—	0.20	61.3	24,587	1,936	288	17.7	0.34
LAURUSLABS	+5.9	+32.7	+83.2	+129.9	+421.9	+235.3	88.9	21.09	18.2	17.9	—	0.45	62.0	1.12L	8,839	1,252	23.3	0.74
ZIMLAB	+2.0	+14.2	+73.3	+101.9	+17.5	—	168.5	2.50	2.1	5.5	—	0.42	21.1	740	397	4	0.8	0.75
ACUTAAS	-5.4	-11.0	+35.0	+97.5	—	—	69.0	16.11	24.0	31.7	—	0.02	49.9	26,636	1,462	387	47.2	0.77
IOLCP	-9.8	+17.8	+108.9	+87.8	+99.0	+56.2	32.0	2.99	7.9	10.7	—	0.07	20.7	5,376	2,524	168	5.7	1.13

A blank in a return column means the stock is younger than that window. P/B and ROE come from each company's own filings where held.

Pharma stocks of a similar size

GSK Pharma Anthem Biosciences Limited IPCA Laboratories Gland Pharma Emcure Pharmaceuticals Limited Abbott India Wockpharma Biocon

The live scanner - every stock ranked, filtered by method, stage and sector, with interactive charts - is in the StockLearn app. Open the StockLearn scanner →

Prices as of 2026-10-19, end of day, from NSE. Fundamentals from each company's own exchange filings (XBRL), EPS restated for splits and bonuses. Figures may be delayed and are for information only.

For research & education only — not investment advice. The methods, checks and verdicts are automated rules applied to public data, not buy/sell recommendations. StockLearn is an independent product of ClusterMicro Technologies, not affiliated with or endorsed by the NSE or any exchange. ClusterMicro Technologies is not a SEBI-registered investment adviser. Consult a SEBI-registered adviser before investing.

Terms · Privacy · Disclaimer · Refund · Contact